News

News 05.12.2025 Zurich, Switzerland - 04.12.2025 Neurimmune today announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease by entering into an exclusive global collaboration and license agreement to develop NI009, a preclinical human monoclonal antibody designed to target and deplete lambda light chain fibrils and deposits...

News 03.12.2025 CUTISS is pleased to share that the 1-year results of the Phase IIb clinical trial evaluating denovoSkin™ in adolescent and adult burn patients have been published in eClinicalMedicine, part of The Lancet Discovery Science. The prospective, randomized, controlled multicenter study compared denovoSkin™ to split-thickness skin grafts, the current surgical standard. The...

News 02.12.2025 Schlieren (Zürich), Switzerland, December 2, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced that the first patient has been enrolled in its global ASTRA (Ankle Subtalar arThrodesis Randomized Assessment) study. ASTRA is a prospective, randomized, single-blinded, controlled, multi-center study to assess the...

News 21.11.2025 CUTISS has been awarded 2nd place at the 2025 edition of The Spark – Der Deutsche Digitalpreis, which recognizes outstanding deep-tech innovation across Germany, Austria, and Switzerland. The award ceremony in Munich brought together finalists from across a range of industries. CUTISS was recognized for its pioneering work in personalized regenerative...

Events, External events
Event date: 27.11.2025 Webinar: 11:30h - 13:00h The Aryastha Biosolutions® Platform offers a comprehensive suite of advanced human-relevant preclinical models—including Patient-Derived Cells (PDCs), Tumor Organoids (PDTOs), Tumor Slice Cultures (PTSCs), and iTOX stem-cell–based toxicity models. These systems bridge the translational gap between in vitro research and clinical response, supporting Phase 0 trials to enhance...